ES2363795T3 - Compuestos de pirazolo[3,4-b]piridina, y su uso como inhibidores de pde4. - Google Patents
Compuestos de pirazolo[3,4-b]piridina, y su uso como inhibidores de pde4. Download PDFInfo
- Publication number
- ES2363795T3 ES2363795T3 ES06779578T ES06779578T ES2363795T3 ES 2363795 T3 ES2363795 T3 ES 2363795T3 ES 06779578 T ES06779578 T ES 06779578T ES 06779578 T ES06779578 T ES 06779578T ES 2363795 T3 ES2363795 T3 ES 2363795T3
- Authority
- ES
- Spain
- Prior art keywords
- methyl
- ring
- alkyl
- formula
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 328
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title description 57
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 title description 55
- -1 C1-2fluoroalkyl Chemical group 0.000 claims abstract description 278
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 247
- 150000003839 salts Chemical class 0.000 claims abstract description 227
- 125000003709 fluoroalkyl group Chemical group 0.000 claims abstract description 95
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 85
- 238000011282 treatment Methods 0.000 claims abstract description 63
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 53
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims abstract description 39
- 238000011321 prophylaxis Methods 0.000 claims abstract description 36
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 22
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract description 20
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims abstract description 15
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims abstract description 14
- 208000026935 allergic disease Diseases 0.000 claims abstract description 10
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims abstract description 10
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 7
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims abstract description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 171
- 125000001424 substituent group Chemical group 0.000 claims description 146
- 229910052799 carbon Inorganic materials 0.000 claims description 138
- 125000000217 alkyl group Chemical group 0.000 claims description 123
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 113
- 229910052757 nitrogen Inorganic materials 0.000 claims description 98
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 86
- 239000008194 pharmaceutical composition Substances 0.000 claims description 75
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 75
- 229910052731 fluorine Inorganic materials 0.000 claims description 56
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 55
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims description 47
- 239000011737 fluorine Substances 0.000 claims description 45
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 44
- 125000003545 alkoxy group Chemical group 0.000 claims description 43
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 42
- 239000000460 chlorine Substances 0.000 claims description 41
- 229910052801 chlorine Inorganic materials 0.000 claims description 40
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 36
- 241000124008 Mammalia Species 0.000 claims description 35
- 239000003814 drug Substances 0.000 claims description 35
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 34
- 201000008937 atopic dermatitis Diseases 0.000 claims description 34
- 229910052739 hydrogen Inorganic materials 0.000 claims description 34
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 34
- 101100294106 Caenorhabditis elegans nhr-3 gene Proteins 0.000 claims description 33
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 27
- 125000001072 heteroaryl group Chemical group 0.000 claims description 27
- 239000001257 hydrogen Substances 0.000 claims description 27
- 125000004429 atom Chemical group 0.000 claims description 25
- 150000001721 carbon Chemical group 0.000 claims description 25
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 25
- 125000001153 fluoro group Chemical group F* 0.000 claims description 24
- 229910052760 oxygen Inorganic materials 0.000 claims description 24
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 23
- 229910052717 sulfur Inorganic materials 0.000 claims description 22
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims description 21
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 claims description 21
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 20
- 101100006941 Caenorhabditis elegans sex-1 gene Proteins 0.000 claims description 19
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 19
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims description 18
- 125000005843 halogen group Chemical group 0.000 claims description 18
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 17
- 125000004076 pyridyl group Chemical group 0.000 claims description 17
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 16
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 15
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims description 15
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 14
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 14
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 14
- 125000006413 ring segment Chemical group 0.000 claims description 14
- 201000010105 allergic rhinitis Diseases 0.000 claims description 13
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 12
- 208000006673 asthma Diseases 0.000 claims description 12
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 12
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 11
- 208000028698 Cognitive impairment Diseases 0.000 claims description 11
- 208000012902 Nervous system disease Diseases 0.000 claims description 11
- 229910052794 bromium Inorganic materials 0.000 claims description 11
- 208000010877 cognitive disease Diseases 0.000 claims description 11
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 10
- 229930194542 Keto Natural products 0.000 claims description 9
- 201000004681 Psoriasis Diseases 0.000 claims description 9
- 230000000172 allergic effect Effects 0.000 claims description 9
- 229910052740 iodine Inorganic materials 0.000 claims description 9
- 125000000468 ketone group Chemical group 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims description 7
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 7
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 7
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 7
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 7
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 7
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 7
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims description 6
- 206010040070 Septic Shock Diseases 0.000 claims description 6
- 208000010668 atopic eczema Diseases 0.000 claims description 6
- 125000002541 furyl group Chemical group 0.000 claims description 6
- 125000002883 imidazolyl group Chemical group 0.000 claims description 6
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 6
- 125000002971 oxazolyl group Chemical group 0.000 claims description 6
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 6
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 6
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 6
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 6
- 125000000335 thiazolyl group Chemical group 0.000 claims description 6
- 125000001544 thienyl group Chemical group 0.000 claims description 6
- 125000001425 triazolyl group Chemical group 0.000 claims description 6
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims description 5
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 claims description 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 5
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 5
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 5
- 201000000980 schizophrenia Diseases 0.000 claims description 5
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 206010014824 Endotoxic shock Diseases 0.000 claims description 3
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims description 3
- 206010065390 Inflammatory pain Diseases 0.000 claims description 3
- 206010069698 Langerhans' cell histiocytosis Diseases 0.000 claims description 3
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims description 3
- 208000024780 Urticaria Diseases 0.000 claims description 3
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims description 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 3
- 125000002619 bicyclic group Chemical group 0.000 claims description 3
- 208000003401 eosinophilic granuloma Diseases 0.000 claims description 3
- 201000004193 respiratory failure Diseases 0.000 claims description 3
- 230000036303 septic shock Effects 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 201000005539 vernal conjunctivitis Diseases 0.000 claims description 3
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 2
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract description 11
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract description 11
- 239000003112 inhibitor Substances 0.000 abstract description 10
- 230000002757 inflammatory effect Effects 0.000 abstract description 9
- 239000000203 mixture Substances 0.000 description 108
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 104
- 238000000034 method Methods 0.000 description 92
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 70
- 239000003921 oil Substances 0.000 description 59
- 235000019198 oils Nutrition 0.000 description 57
- 241000282414 Homo sapiens Species 0.000 description 53
- 241000700159 Rattus Species 0.000 description 51
- 238000006243 chemical reaction Methods 0.000 description 49
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 47
- 239000002674 ointment Substances 0.000 description 46
- 239000002904 solvent Substances 0.000 description 44
- 239000006071 cream Substances 0.000 description 41
- 239000012071 phase Substances 0.000 description 41
- 239000000243 solution Substances 0.000 description 40
- 230000000699 topical effect Effects 0.000 description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- 239000000463 material Substances 0.000 description 35
- 239000002158 endotoxin Substances 0.000 description 34
- 230000005764 inhibitory process Effects 0.000 description 33
- 239000000843 powder Substances 0.000 description 33
- 238000012360 testing method Methods 0.000 description 33
- 229920006008 lipopolysaccharide Polymers 0.000 description 32
- 239000002245 particle Substances 0.000 description 32
- 229940079593 drug Drugs 0.000 description 31
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 30
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 29
- 238000003556 assay Methods 0.000 description 28
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 26
- 241001465754 Metazoa Species 0.000 description 26
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 26
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 26
- 230000000694 effects Effects 0.000 description 25
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 24
- 229960001375 lactose Drugs 0.000 description 24
- 239000008101 lactose Substances 0.000 description 24
- 239000002585 base Substances 0.000 description 23
- 239000000543 intermediate Substances 0.000 description 23
- 238000011200 topical administration Methods 0.000 description 23
- 238000001727 in vivo Methods 0.000 description 22
- 230000003110 anti-inflammatory effect Effects 0.000 description 21
- 239000003961 penetration enhancing agent Substances 0.000 description 21
- 231100001274 therapeutic index Toxicity 0.000 description 21
- 150000001412 amines Chemical class 0.000 description 19
- 239000000839 emulsion Substances 0.000 description 19
- 239000000725 suspension Substances 0.000 description 19
- 239000003871 white petrolatum Substances 0.000 description 19
- 101000988424 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4B Proteins 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 206010047700 Vomiting Diseases 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 17
- 102100029168 cAMP-specific 3',5'-cyclic phosphodiesterase 4B Human genes 0.000 description 16
- 239000004205 dimethyl polysiloxane Substances 0.000 description 16
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 16
- 239000008309 hydrophilic cream Substances 0.000 description 16
- 239000003981 vehicle Substances 0.000 description 16
- 206010029379 Neutrophilia Diseases 0.000 description 15
- 238000002875 fluorescence polarization Methods 0.000 description 15
- JSPCTNUQYWIIOT-UHFFFAOYSA-N piperidine-1-carboxamide Chemical compound NC(=O)N1CCCCC1 JSPCTNUQYWIIOT-UHFFFAOYSA-N 0.000 description 15
- 241001482237 Pica Species 0.000 description 14
- 239000007789 gas Substances 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- 102000014974 beta2-adrenergic receptor activity proteins Human genes 0.000 description 13
- 108040006828 beta2-adrenergic receptor activity proteins Proteins 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 239000003960 organic solvent Substances 0.000 description 13
- 229920002675 Polyoxyl Polymers 0.000 description 12
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
- 239000002895 emetic Substances 0.000 description 12
- 235000013305 food Nutrition 0.000 description 12
- 239000008308 lipophilic cream Substances 0.000 description 12
- 238000005259 measurement Methods 0.000 description 12
- 239000003883 ointment base Substances 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 239000004094 surface-active agent Substances 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 239000012458 free base Substances 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 235000019271 petrolatum Nutrition 0.000 description 11
- 229940068196 placebo Drugs 0.000 description 11
- 239000000902 placebo Substances 0.000 description 11
- 229920002545 silicone oil Polymers 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 239000000048 adrenergic agonist Substances 0.000 description 10
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 10
- 239000004927 clay Substances 0.000 description 10
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 10
- 238000007911 parenteral administration Methods 0.000 description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 9
- 206010015150 Erythema Diseases 0.000 description 9
- 241000282887 Suidae Species 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 9
- 229940008099 dimethicone Drugs 0.000 description 9
- 239000003937 drug carrier Substances 0.000 description 9
- 231100000321 erythema Toxicity 0.000 description 9
- 230000000670 limiting effect Effects 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 210000000440 neutrophil Anatomy 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 230000005951 type IV hypersensitivity Effects 0.000 description 9
- 241000283690 Bos taurus Species 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 8
- 241000282341 Mustela putorius furo Species 0.000 description 8
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 8
- 101710135349 Venom phosphodiesterase Proteins 0.000 description 8
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000003246 corticosteroid Substances 0.000 description 8
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 8
- 239000003974 emollient agent Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000000227 grinding Methods 0.000 description 8
- 150000005230 pyrazolo[3,4-b]pyridines Chemical class 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 210000003437 trachea Anatomy 0.000 description 8
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 8
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 7
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 7
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 239000003149 muscarinic antagonist Substances 0.000 description 7
- 229910052705 radium Inorganic materials 0.000 description 7
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 6
- AMFYRKOUWBAGHV-UHFFFAOYSA-N 1h-pyrazolo[4,3-b]pyridine Chemical compound C1=CN=C2C=NNC2=C1 AMFYRKOUWBAGHV-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 6
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 6
- 108010081348 HRT1 protein Hairy Proteins 0.000 description 6
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 description 6
- 101000988419 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4D Proteins 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000282339 Mustela Species 0.000 description 6
- 229920005439 Perspex® Polymers 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 239000000443 aerosol Substances 0.000 description 6
- 230000001078 anti-cholinergic effect Effects 0.000 description 6
- 229960005475 antiinfective agent Drugs 0.000 description 6
- 239000004599 antimicrobial Substances 0.000 description 6
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 102100029170 cAMP-specific 3',5'-cyclic phosphodiesterase 4D Human genes 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 description 6
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 6
- 239000003018 immunosuppressive agent Substances 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 239000004926 polymethyl methacrylate Substances 0.000 description 6
- 230000002685 pulmonary effect Effects 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 239000012049 topical pharmaceutical composition Substances 0.000 description 6
- GVPDNFYOFKBFEN-UHFFFAOYSA-N trimethyl(octadecoxy)silane Chemical compound CCCCCCCCCCCCCCCCCCO[Si](C)(C)C GVPDNFYOFKBFEN-UHFFFAOYSA-N 0.000 description 6
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 5
- UWCWUCKPEYNDNV-LBPRGKRZSA-N 2,6-dimethyl-n-[[(2s)-pyrrolidin-2-yl]methyl]aniline Chemical compound CC1=CC=CC(C)=C1NC[C@H]1NCCC1 UWCWUCKPEYNDNV-LBPRGKRZSA-N 0.000 description 5
- 101100135868 Dictyostelium discoideum pde3 gene Proteins 0.000 description 5
- 101100351286 Dictyostelium discoideum pdeE gene Proteins 0.000 description 5
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 description 5
- 150000003857 carboxamides Chemical class 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 229940086555 cyclomethicone Drugs 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 150000002431 hydrogen Chemical group 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 229960003444 immunosuppressant agent Drugs 0.000 description 5
- 230000001861 immunosuppressant effect Effects 0.000 description 5
- 238000004811 liquid chromatography Methods 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 239000002480 mineral oil Substances 0.000 description 5
- 235000010446 mineral oil Nutrition 0.000 description 5
- IVCULVDQDDNNGL-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-5-methylpyrazine-2-carboxamide Chemical compound C=1N=C(C)C=NC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 IVCULVDQDDNNGL-UHFFFAOYSA-N 0.000 description 5
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 5
- 239000006199 nebulizer Substances 0.000 description 5
- 239000002547 new drug Substances 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 239000012188 paraffin wax Substances 0.000 description 5
- 101150037969 pde-6 gene Proteins 0.000 description 5
- 229910052701 rubidium Inorganic materials 0.000 description 5
- 229960004017 salmeterol Drugs 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 5
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 description 4
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 4
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 4
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 4
- 102000017925 CHRM3 Human genes 0.000 description 4
- 101150060249 CHRM3 gene Proteins 0.000 description 4
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 101150098694 PDE5A gene Proteins 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 229950006790 adenosine phosphate Drugs 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 239000002168 alkylating agent Substances 0.000 description 4
- 229940100198 alkylating agent Drugs 0.000 description 4
- 238000005804 alkylation reaction Methods 0.000 description 4
- 230000001387 anti-histamine Effects 0.000 description 4
- 239000000739 antihistaminic agent Substances 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000004945 emulsification Methods 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000013401 experimental design Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- KASDHRXLYQOAKZ-XDSKOBMDSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-XDSKOBMDSA-N 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000003380 propellant Substances 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- 229940044551 receptor antagonist Drugs 0.000 description 4
- 239000002464 receptor antagonist Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 206010039083 rhinitis Diseases 0.000 description 4
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 4
- 229960002586 roflumilast Drugs 0.000 description 4
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 4
- 229950005741 rolipram Drugs 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 3
- JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical compound NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 3
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 3
- 206010006458 Bronchitis chronic Diseases 0.000 description 3
- 125000006539 C12 alkyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 206010014561 Emphysema Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- 241000219739 Lens Species 0.000 description 3
- 206010025421 Macule Diseases 0.000 description 3
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 3
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 3
- WOTQVEKSRLZRSX-HYSGBLIFSA-N [(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1O[C@H]1[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1 WOTQVEKSRLZRSX-HYSGBLIFSA-N 0.000 description 3
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 3
- 230000010933 acylation Effects 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 239000003125 aqueous solvent Substances 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- WOTQVEKSRLZRSX-UHFFFAOYSA-N beta-D-cellobioside octaacetate Natural products CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1 WOTQVEKSRLZRSX-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 208000007451 chronic bronchitis Diseases 0.000 description 3
- 229950001653 cilomilast Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 238000009795 derivation Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 229940082337 dimethicone 20 Drugs 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 229960004979 fampridine Drugs 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 3
- 229960000289 fluticasone propionate Drugs 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 238000004817 gas chromatography Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000002794 lymphocyte assay Methods 0.000 description 3
- 239000004200 microcrystalline wax Substances 0.000 description 3
- 235000019808 microcrystalline wax Nutrition 0.000 description 3
- ZJGFHUMEHNYWOR-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-1-methylpyrazole-3-carboxamide Chemical compound C1=CN(C)N=C1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 ZJGFHUMEHNYWOR-UHFFFAOYSA-N 0.000 description 3
- PBQZQTQFQFYBNJ-UHFFFAOYSA-N n-methoxybenzamide Chemical compound CONC(=O)C1=CC=CC=C1 PBQZQTQFQFYBNJ-UHFFFAOYSA-N 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 229960005330 pimecrolimus Drugs 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000007928 solubilization Effects 0.000 description 3
- 238000005063 solubilization Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 229960001967 tacrolimus Drugs 0.000 description 3
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 3
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 description 2
- AFXUAEAIXDBZOX-UHFFFAOYSA-N 1,3-diazaspiro[4.5]decan-2-one Chemical compound N1C(=O)NCC11CCCCC1 AFXUAEAIXDBZOX-UHFFFAOYSA-N 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- FZZMTSNZRBFGGU-UHFFFAOYSA-N 2-chloro-7-fluoroquinazolin-4-amine Chemical compound FC1=CC=C2C(N)=NC(Cl)=NC2=C1 FZZMTSNZRBFGGU-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- 101100294115 Caenorhabditis elegans nhr-4 gene Proteins 0.000 description 2
- 101100135867 Caenorhabditis elegans pde-3 gene Proteins 0.000 description 2
- 101100296726 Caenorhabditis elegans pde-5 gene Proteins 0.000 description 2
- 101100351285 Caenorhabditis elegans pde-6 gene Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 235000014647 Lens culinaris subsp culinaris Nutrition 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010038776 Retching Diseases 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 2
- XSYFDCWZBXZVIP-UHFFFAOYSA-N [N].C1=CN=C2C=NNC2=C1 Chemical group [N].C1=CN=C2C=NNC2=C1 XSYFDCWZBXZVIP-UHFFFAOYSA-N 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000004479 aerosol dispenser Substances 0.000 description 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 150000001408 amides Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000008135 aqueous vehicle Substances 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000005660 chlorination reaction Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- BMCQMVFGOVHVNG-TUFAYURCSA-N cortisol 17-butyrate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O BMCQMVFGOVHVNG-TUFAYURCSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000003821 enantio-separation Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 2
- 229960002848 formoterol Drugs 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid group Chemical group C(CCCCC)(=O)O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 229960001524 hydrocortisone butyrate Drugs 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 229910052747 lanthanoid Inorganic materials 0.000 description 2
- 150000002602 lanthanoids Chemical class 0.000 description 2
- GUWHRJQTTVADPB-UHFFFAOYSA-N lithium azide Chemical compound [Li+].[N-]=[N+]=[N-] GUWHRJQTTVADPB-UHFFFAOYSA-N 0.000 description 2
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- ANNZEGGTCVFWRN-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-2-methylfuran-3-carboxamide Chemical compound C1=COC(C)=C1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 ANNZEGGTCVFWRN-UHFFFAOYSA-N 0.000 description 2
- IEAAPZQFLDBHCF-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-3-methyl-1,2-oxazole-5-carboxamide Chemical compound C=1C(C)=NOC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 IEAAPZQFLDBHCF-UHFFFAOYSA-N 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 238000010951 particle size reduction Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 2
- 238000013310 pig model Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 2
- 229910000105 potassium hydride Inorganic materials 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 2
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 229960002052 salbutamol Drugs 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical class O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000017105 transposition Effects 0.000 description 2
- ZISSAWUMDACLOM-UHFFFAOYSA-N triptane Chemical compound CC(C)C(C)(C)C ZISSAWUMDACLOM-UHFFFAOYSA-N 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- OBETXYAYXDNJHR-SSDOTTSWSA-M (2r)-2-ethylhexanoate Chemical compound CCCC[C@@H](CC)C([O-])=O OBETXYAYXDNJHR-SSDOTTSWSA-M 0.000 description 1
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 description 1
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 1
- OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical class OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 description 1
- YKYIFUROKBDHCY-ONEGZZNKSA-N (e)-4-ethoxy-1,1,1-trifluorobut-3-en-2-one Chemical group CCO\C=C\C(=O)C(F)(F)F YKYIFUROKBDHCY-ONEGZZNKSA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- BXQZTISGEVKWHM-UHFFFAOYSA-N 1,3,2-diazaphosphinane Chemical compound C1CNPNC1 BXQZTISGEVKWHM-UHFFFAOYSA-N 0.000 description 1
- VAELWSLNTRVXQS-UHFFFAOYSA-N 1,3-oxazole-4-carboxamide Chemical compound NC(=O)C1=COC=N1 VAELWSLNTRVXQS-UHFFFAOYSA-N 0.000 description 1
- NDZYPHLNJZSQJY-QNWVGRARSA-N 1-(5-acetyl-4-methyl-1,3-thiazol-2-yl)-3-[(1r,2s)-2-[[(3s)-3-[(4-fluorophenyl)methyl]piperidin-1-yl]methyl]cyclohexyl]urea Chemical compound CC1=C(C(=O)C)SC(NC(=O)N[C@H]2[C@@H](CCCC2)CN2C[C@H](CC=3C=CC(F)=CC=3)CCC2)=N1 NDZYPHLNJZSQJY-QNWVGRARSA-N 0.000 description 1
- JIDGSZPVHQTNKR-UHFFFAOYSA-N 1-[4-[4-[[1-ethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]piperazin-1-yl]phenyl]ethanone Chemical compound C1CN(C=2C=CC(=CC=2)C(C)=O)CCN1CC1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 JIDGSZPVHQTNKR-UHFFFAOYSA-N 0.000 description 1
- DCDJSAGSAIZKAZ-UHFFFAOYSA-N 1-[4-[4-[[1-ethyl-6-methyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]piperazin-1-yl]phenyl]ethanone Chemical compound C1CN(C=2C=CC(=CC=2)C(C)=O)CCN1CC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 DCDJSAGSAIZKAZ-UHFFFAOYSA-N 0.000 description 1
- SYWNAZREJCGKQG-UHFFFAOYSA-N 1-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-3-(2-phenylethyl)urea Chemical compound C=1C=CC=CC=1CCNC(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 SYWNAZREJCGKQG-UHFFFAOYSA-N 0.000 description 1
- JFUCAMBURFSHFG-UHFFFAOYSA-N 1-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-3-phenylurea Chemical compound C=1C=CC=CC=1NC(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 JFUCAMBURFSHFG-UHFFFAOYSA-N 0.000 description 1
- KJZBTLSCGQFGHL-UHFFFAOYSA-N 1-[[1-ethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-3-methylimidazolidin-2-one Chemical compound C1CN(C)C(=O)N1CC1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 KJZBTLSCGQFGHL-UHFFFAOYSA-N 0.000 description 1
- MNUXVCYKCLDGRI-UHFFFAOYSA-N 1-[[1-ethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-phenylpiperidine-4-carbonitrile Chemical compound C1CC(C=2C=CC=CC=2)(C#N)CCN1CC1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 MNUXVCYKCLDGRI-UHFFFAOYSA-N 0.000 description 1
- ZYWYXGZWLCZOIE-UHFFFAOYSA-N 1-[[1-ethyl-6-methyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-3-methylimidazolidin-2-one Chemical compound C1CN(C)C(=O)N1CC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 ZYWYXGZWLCZOIE-UHFFFAOYSA-N 0.000 description 1
- BPWVJAIDIBLTBL-UHFFFAOYSA-N 1-[[1-ethyl-6-methyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-phenylpiperidine-4-carbonitrile Chemical compound C1CC(C=2C=CC=CC=2)(C#N)CCN1CC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 BPWVJAIDIBLTBL-UHFFFAOYSA-N 0.000 description 1
- GGSZAKZQKYQHLX-UHFFFAOYSA-N 1-[[1-ethyl-6-methyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]piperidin-2-one Chemical compound C1CCCC(=O)N1CC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 GGSZAKZQKYQHLX-UHFFFAOYSA-N 0.000 description 1
- OPBFBHXKFBKEDL-UHFFFAOYSA-N 1-[[1-ethyl-6-methyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]pyrrolidin-2-one Chemical compound C1CCC(=O)N1CC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 OPBFBHXKFBKEDL-UHFFFAOYSA-N 0.000 description 1
- ZJTRTYDDTFBLBP-UHFFFAOYSA-N 1-acetyl-n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]piperidine-4-carboxamide Chemical compound C1CN(C(C)=O)CCC1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 ZJTRTYDDTFBLBP-UHFFFAOYSA-N 0.000 description 1
- WAGAKJVLSCURKP-UHFFFAOYSA-N 1-acetyl-n-[[1-ethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]piperidine-4-carboxamide Chemical compound C1CN(C(C)=O)CCC1C(=O)NCC1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 WAGAKJVLSCURKP-UHFFFAOYSA-N 0.000 description 1
- VMABSWBAYDVFRB-UHFFFAOYSA-N 1-acetyl-n-[[1-ethyl-6-methyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]piperidine-4-carboxamide Chemical compound C1CN(C(C)=O)CCC1C(=O)NCC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 VMABSWBAYDVFRB-UHFFFAOYSA-N 0.000 description 1
- HBNDGVZJHPBHEC-UHFFFAOYSA-N 1-benzyl-3-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]urea Chemical compound C=1C=CC=CC=1CNC(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 HBNDGVZJHPBHEC-UHFFFAOYSA-N 0.000 description 1
- PLULROWJNMIEBR-UHFFFAOYSA-N 1-ethyl-5-[(4-ethylsulfonylpiperazin-1-yl)methyl]-6-methyl-n-(oxan-4-yl)pyrazolo[3,4-b]pyridin-4-amine Chemical compound C1CN(S(=O)(=O)CC)CCN1CC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 PLULROWJNMIEBR-UHFFFAOYSA-N 0.000 description 1
- BDJIDHBRLWGBCL-UHFFFAOYSA-N 1-ethyl-5-[(4-ethylsulfonylpiperazin-1-yl)methyl]-n-(oxan-4-yl)pyrazolo[3,4-b]pyridin-4-amine Chemical compound C1CN(S(=O)(=O)CC)CCN1CC1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 BDJIDHBRLWGBCL-UHFFFAOYSA-N 0.000 description 1
- LOTLBRIOSLSBCB-UHFFFAOYSA-N 1-ethyl-5-[[4-(3-methylphenyl)piperazin-1-yl]methyl]-n-(oxan-4-yl)pyrazolo[3,4-b]pyridin-4-amine Chemical compound C1CN(C=2C=C(C)C=CC=2)CCN1CC1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 LOTLBRIOSLSBCB-UHFFFAOYSA-N 0.000 description 1
- ALJSNQNDDNNGOX-UHFFFAOYSA-N 1-ethyl-5-[[4-[1-(3-methoxyphenyl)ethyl]piperazin-1-yl]methyl]-n-(oxan-4-yl)pyrazolo[3,4-b]pyridin-4-amine Chemical compound C1CN(C(C)C=2C=C(OC)C=CC=2)CCN1CC1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 ALJSNQNDDNNGOX-UHFFFAOYSA-N 0.000 description 1
- VXCZWEREGVMQCI-UHFFFAOYSA-N 1-ethyl-5-[[methyl(pyridin-3-ylmethyl)amino]methyl]-n-(oxan-4-yl)pyrazolo[3,4-b]pyridin-4-amine Chemical compound C=1C=CN=CC=1CN(C)CC1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 VXCZWEREGVMQCI-UHFFFAOYSA-N 0.000 description 1
- ZBBDGWLEYWCINI-UHFFFAOYSA-N 1-ethyl-6-methyl-5-[[methyl(pyridin-3-ylmethyl)amino]methyl]-n-(oxan-4-yl)pyrazolo[3,4-b]pyridin-4-amine Chemical compound C=1C=CN=CC=1CN(C)CC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 ZBBDGWLEYWCINI-UHFFFAOYSA-N 0.000 description 1
- QMUZCVZRKGPWDN-UHFFFAOYSA-N 1-ethyl-6-methyl-n-(oxan-4-yl)-5-[(4-pyrimidin-2-ylpiperazin-1-yl)methyl]pyrazolo[3,4-b]pyridin-4-amine Chemical compound C1CN(C=2N=CC=CN=2)CCN1CC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 QMUZCVZRKGPWDN-UHFFFAOYSA-N 0.000 description 1
- NNEWBYXDUCQPPW-UHFFFAOYSA-N 1-ethyl-6-methyl-n-(oxan-4-yl)-5-[(pyridin-3-ylmethylamino)methyl]pyrazolo[3,4-b]pyridin-4-amine Chemical compound C=1C=CN=CC=1CNCC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 NNEWBYXDUCQPPW-UHFFFAOYSA-N 0.000 description 1
- GLQOXBOLFWOEOP-UHFFFAOYSA-N 1-ethyl-n-(oxan-4-yl)-5-[(4-phenylpiperidin-1-yl)methyl]pyrazolo[3,4-b]pyridin-4-amine Chemical compound C1CC(C=2C=CC=CC=2)CCN1CC1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 GLQOXBOLFWOEOP-UHFFFAOYSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- ILCOCZBHMDEIAI-UHFFFAOYSA-N 2-(2-octadecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCO ILCOCZBHMDEIAI-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- MOUMWGGUPATGFF-UHFFFAOYSA-N 2-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-3h-isoindol-1-one Chemical compound C1C2=CC=CC=C2C(=O)N1CC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 MOUMWGGUPATGFF-UHFFFAOYSA-N 0.000 description 1
- CZCIYCBCIABXGD-UHFFFAOYSA-N 2-[[1-ethyl-6-methyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-3h-isoindol-1-one Chemical compound C1C2=CC=CC=C2C(=O)N1CC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 CZCIYCBCIABXGD-UHFFFAOYSA-N 0.000 description 1
- SFAAOBGYWOUHLU-UHFFFAOYSA-N 2-ethylhexyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC SFAAOBGYWOUHLU-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 description 1
- ZZOMTUDSENHZNT-UHFFFAOYSA-N 2-phenylbenzene-1,3-dicarboxamide Chemical compound NC(=O)C1=CC=CC(C(N)=O)=C1C1=CC=CC=C1 ZZOMTUDSENHZNT-UHFFFAOYSA-N 0.000 description 1
- VSCBATMPTLKTOV-UHFFFAOYSA-N 2-tert-butylimino-n,n-diethyl-1,3-dimethyl-1,3,2$l^{5}-diazaphosphinan-2-amine Chemical compound CCN(CC)P1(=NC(C)(C)C)N(C)CCCN1C VSCBATMPTLKTOV-UHFFFAOYSA-N 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- ULHJDHUVUALYSL-UHFFFAOYSA-N 3-[1-[[1-ethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]piperidin-3-yl]-1-(4-hydroxyphenyl)propan-1-one Chemical compound C1CCC(CCC(=O)C=2C=CC(O)=CC=2)CN1CC1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 ULHJDHUVUALYSL-UHFFFAOYSA-N 0.000 description 1
- GBTODAKMABNGIJ-VWLOTQADSA-N 3-[4-[6-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]hexoxy]butyl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC(CCCCOCCCCCCNC[C@H](O)C=2C=C(CO)C(O)=CC=2)=C1 GBTODAKMABNGIJ-VWLOTQADSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- VIHRIIARIFUQLC-UHFFFAOYSA-N 3-hydrazinylpropanenitrile Chemical compound NNCCC#N VIHRIIARIFUQLC-UHFFFAOYSA-N 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- PPJBHOYAHZSNDB-UHFFFAOYSA-N 4-[4-[[1-ethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]piperazin-1-yl]benzonitrile Chemical compound C1CN(C=2C=CC(=CC=2)C#N)CCN1CC1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 PPJBHOYAHZSNDB-UHFFFAOYSA-N 0.000 description 1
- RDDXERWHJAZIII-UHFFFAOYSA-N 4-[[1,6-diethyl-5-[(3-oxo-1h-isoindol-2-yl)methyl]pyrazolo[3,4-b]pyridin-4-yl]amino]piperidine-1-carboxamide Chemical compound C1C2=CC=CC=C2C(=O)N1CC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCN(C(N)=O)CC1 RDDXERWHJAZIII-UHFFFAOYSA-N 0.000 description 1
- JGWNHSQWYWQVPM-UHFFFAOYSA-N 4-[[1,6-diethyl-5-[(furan-2-carbonylamino)methyl]pyrazolo[3,4-b]pyridin-4-yl]amino]piperidine-1-carboxamide Chemical compound C=1C=COC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCN(C(N)=O)CC1 JGWNHSQWYWQVPM-UHFFFAOYSA-N 0.000 description 1
- GBNKUCLQXNBCDS-UHFFFAOYSA-N 4-[[1,6-diethyl-5-[[(2-fluorobenzoyl)amino]methyl]pyrazolo[3,4-b]pyridin-4-yl]amino]piperidine-1-carboxamide Chemical compound C=1C=CC=C(F)C=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCN(C(N)=O)CC1 GBNKUCLQXNBCDS-UHFFFAOYSA-N 0.000 description 1
- NAWASODSJXVCSQ-UHFFFAOYSA-N 4-[[1,6-diethyl-5-[[(2-hydroxybenzoyl)amino]methyl]pyrazolo[3,4-b]pyridin-4-yl]amino]piperidine-1-carboxamide Chemical compound C=1C=CC=C(O)C=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCN(C(N)=O)CC1 NAWASODSJXVCSQ-UHFFFAOYSA-N 0.000 description 1
- CBISJOSQRPPARR-UHFFFAOYSA-N 4-[[1,6-diethyl-5-[[(4-morpholin-4-ylbenzoyl)amino]methyl]pyrazolo[3,4-b]pyridin-4-yl]amino]piperidine-1-carboxamide Chemical compound C=1C=C(N2CCOCC2)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCN(C(N)=O)CC1 CBISJOSQRPPARR-UHFFFAOYSA-N 0.000 description 1
- SYXSCGBMVRPTSZ-UHFFFAOYSA-N 4-[[1-ethyl-5-[[(2-fluorobenzoyl)amino]methyl]-6-methylpyrazolo[3,4-b]pyridin-4-yl]amino]piperidine-1-carboxamide Chemical compound C=1C=CC=C(F)C=1C(=O)NCC1=C(C)N=C2N(CC)N=CC2=C1NC1CCN(C(N)=O)CC1 SYXSCGBMVRPTSZ-UHFFFAOYSA-N 0.000 description 1
- RZRVRSFHBQLJCH-UHFFFAOYSA-N 4-[[1-ethyl-5-[[(2-hydroxybenzoyl)amino]methyl]-6-methylpyrazolo[3,4-b]pyridin-4-yl]amino]piperidine-1-carboxamide Chemical compound C=1C=CC=C(O)C=1C(=O)NCC1=C(C)N=C2N(CC)N=CC2=C1NC1CCN(C(N)=O)CC1 RZRVRSFHBQLJCH-UHFFFAOYSA-N 0.000 description 1
- URQOCHVYAROYLJ-UHFFFAOYSA-N 4-[[1-ethyl-6-methyl-5-[[(4-methylsulfonylbenzoyl)amino]methyl]pyrazolo[3,4-b]pyridin-4-yl]amino]piperidine-1-carboxamide Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C(=O)NCC1=C(C)N=C2N(CC)N=CC2=C1NC1CCN(C(N)=O)CC1 URQOCHVYAROYLJ-UHFFFAOYSA-N 0.000 description 1
- UVTKESCQEBBPQZ-UHFFFAOYSA-N 4-[[5-[(2,3-dihydro-1-benzofuran-7-carbonylamino)methyl]-1,6-diethylpyrazolo[3,4-b]pyridin-4-yl]amino]piperidine-1-carboxamide Chemical compound C=1C=CC=2CCOC=2C=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCN(C(N)=O)CC1 UVTKESCQEBBPQZ-UHFFFAOYSA-N 0.000 description 1
- KFMYSUBQWCRKAZ-UHFFFAOYSA-N 4-[[5-[[(3-acetamidobenzoyl)amino]methyl]-1,6-diethylpyrazolo[3,4-b]pyridin-4-yl]amino]piperidine-1-carboxamide Chemical compound C=1C=CC(NC(C)=O)=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCN(C(N)=O)CC1 KFMYSUBQWCRKAZ-UHFFFAOYSA-N 0.000 description 1
- DORCYMRWNZCWST-UHFFFAOYSA-N 4-[[5-[[(3-acetamidobenzoyl)amino]methyl]-1-ethyl-6-methylpyrazolo[3,4-b]pyridin-4-yl]amino]piperidine-1-carboxamide Chemical compound C=1C=CC(NC(C)=O)=CC=1C(=O)NCC1=C(C)N=C2N(CC)N=CC2=C1NC1CCN(C(N)=O)CC1 DORCYMRWNZCWST-UHFFFAOYSA-N 0.000 description 1
- IUOMJBTVLYKJQE-UHFFFAOYSA-N 4-[[5-[[(4-acetamido-2,3-dihydro-1-benzofuran-7-carbonyl)amino]methyl]-1,6-diethylpyrazolo[3,4-b]pyridin-4-yl]amino]piperidine-1-carboxamide Chemical compound C=1C=C(NC(C)=O)C=2CCOC=2C=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCN(C(N)=O)CC1 IUOMJBTVLYKJQE-UHFFFAOYSA-N 0.000 description 1
- WSJBERTUUJKSHM-UHFFFAOYSA-N 4-[[5-[[(4-acetamidobenzoyl)amino]methyl]-1,6-diethylpyrazolo[3,4-b]pyridin-4-yl]amino]piperidine-1-carboxamide Chemical compound C=1C=C(NC(C)=O)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCN(C(N)=O)CC1 WSJBERTUUJKSHM-UHFFFAOYSA-N 0.000 description 1
- MNXFKQSQIXBEMC-UHFFFAOYSA-N 4-[[5-[[(4-cyclopentylbenzoyl)amino]methyl]-1,6-diethylpyrazolo[3,4-b]pyridin-4-yl]amino]piperidine-1-carboxamide Chemical compound C=1C=C(C2CCCC2)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCN(C(N)=O)CC1 MNXFKQSQIXBEMC-UHFFFAOYSA-N 0.000 description 1
- WWZGKHRHZXNUEC-UHFFFAOYSA-N 4-[[5-[[(4-tert-butyl-2-hydroxybenzoyl)amino]methyl]-1,6-diethylpyrazolo[3,4-b]pyridin-4-yl]amino]piperidine-1-carboxamide Chemical compound C=1C=C(C(C)(C)C)C=C(O)C=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCN(C(N)=O)CC1 WWZGKHRHZXNUEC-UHFFFAOYSA-N 0.000 description 1
- BXFPINWREIPVTM-UHFFFAOYSA-N 4-[[5-[[(4-tert-butyl-2-hydroxybenzoyl)amino]methyl]-1-ethyl-6-methylpyrazolo[3,4-b]pyridin-4-yl]amino]piperidine-1-carboxamide Chemical compound C=1C=C(C(C)(C)C)C=C(O)C=1C(=O)NCC1=C(C)N=C2N(CC)N=CC2=C1NC1CCN(C(N)=O)CC1 BXFPINWREIPVTM-UHFFFAOYSA-N 0.000 description 1
- AWGRQQOIEKTDGC-UHFFFAOYSA-N 4-acetamido-n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-2,3-dihydro-1-benzofuran-7-carboxamide Chemical compound C=1C=C(NC(C)=O)C=2CCOC=2C=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 AWGRQQOIEKTDGC-UHFFFAOYSA-N 0.000 description 1
- YOUTVSNHXIGVRW-UHFFFAOYSA-N 4-acetamido-n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-2-hydroxybenzamide Chemical compound C=1C=C(NC(C)=O)C=C(O)C=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 YOUTVSNHXIGVRW-UHFFFAOYSA-N 0.000 description 1
- QFRZUTRXRFTVAF-UHFFFAOYSA-N 4-acetamido-n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]benzamide Chemical compound C=1C=C(NC(C)=O)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 QFRZUTRXRFTVAF-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- QRAOZQGIUIDZQZ-UHFFFAOYSA-N 4-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1,4-benzoxazine Chemical compound C=1C=C2N(C)CCOC2=CC=1B1OC(C)(C)C(C)(C)O1 QRAOZQGIUIDZQZ-UHFFFAOYSA-N 0.000 description 1
- BIJCMUPCKHPTFU-UHFFFAOYSA-N 4-n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-1-n-methylbenzene-1,4-dicarboxamide Chemical compound C=1C=C(C(=O)NC)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 BIJCMUPCKHPTFU-UHFFFAOYSA-N 0.000 description 1
- RSYQMVJDJAPHTJ-UHFFFAOYSA-N 4-n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]benzene-1,4-dicarboxamide Chemical compound C=1C=C(C(N)=O)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 RSYQMVJDJAPHTJ-UHFFFAOYSA-N 0.000 description 1
- QCTWIIKOCWCXKL-UHFFFAOYSA-N 4-n-[[1-ethyl-6-methyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]benzene-1,4-dicarboxamide Chemical compound C=1C=C(C(N)=O)C=CC=1C(=O)NCC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 QCTWIIKOCWCXKL-UHFFFAOYSA-N 0.000 description 1
- VIVKCYHOZPMMJZ-UHFFFAOYSA-N 4-n-[[4-[(1-carbamoylpiperidin-4-yl)amino]-1-ethyl-6-methylpyrazolo[3,4-b]pyridin-5-yl]methyl]-1-n-methylbenzene-1,4-dicarboxamide Chemical compound C=1C=C(C(=O)NC)C=CC=1C(=O)NCC1=C(C)N=C2N(CC)N=CC2=C1NC1CCN(C(N)=O)CC1 VIVKCYHOZPMMJZ-UHFFFAOYSA-N 0.000 description 1
- 229940124125 5 Lipoxygenase inhibitor Drugs 0.000 description 1
- FYTLHYRDGXRYEY-UHFFFAOYSA-N 5-Methyl-3-pyrazolamine Chemical compound CC=1C=C(N)NN=1 FYTLHYRDGXRYEY-UHFFFAOYSA-N 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- SAHQSYRPCXZLAU-UHFFFAOYSA-N 5-[(3,3-dimethylpiperidin-1-yl)methyl]-1-ethyl-n-(oxan-4-yl)pyrazolo[3,4-b]pyridin-4-amine Chemical compound C1CCC(C)(C)CN1CC1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 SAHQSYRPCXZLAU-UHFFFAOYSA-N 0.000 description 1
- GZLZZXYLIXCPHC-UHFFFAOYSA-N 5-[(4-benzylpiperazin-1-yl)methyl]-1-ethyl-6-methyl-n-(oxan-4-yl)pyrazolo[3,4-b]pyridin-4-amine Chemical compound C1CN(CC=2C=CC=CC=2)CCN1CC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 GZLZZXYLIXCPHC-UHFFFAOYSA-N 0.000 description 1
- YNFVNTAJVWQZAB-UHFFFAOYSA-N 5-[(4-benzylpiperazin-1-yl)methyl]-1-ethyl-n-(oxan-4-yl)pyrazolo[3,4-b]pyridin-4-amine Chemical compound C1CN(CC=2C=CC=CC=2)CCN1CC1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 YNFVNTAJVWQZAB-UHFFFAOYSA-N 0.000 description 1
- RHXQZONHBXNUAQ-UHFFFAOYSA-N 5-[(benzylamino)methyl]-1,6-diethyl-n-(oxan-4-yl)pyrazolo[3,4-b]pyridin-4-amine Chemical compound C=1C=CC=CC=1CNCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 RHXQZONHBXNUAQ-UHFFFAOYSA-N 0.000 description 1
- GEKAHYPFYNSPFL-UHFFFAOYSA-N 5-[(benzylamino)methyl]-1-ethyl-6-methyl-n-(oxan-4-yl)pyrazolo[3,4-b]pyridin-4-amine Chemical compound C=1C=CC=CC=1CNCC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 GEKAHYPFYNSPFL-UHFFFAOYSA-N 0.000 description 1
- GBSOCQCTWPFEAX-UHFFFAOYSA-N 5-[(benzylamino)methyl]-1-ethyl-n-(oxan-4-yl)pyrazolo[3,4-b]pyridin-4-amine Chemical compound C=1C=CC=CC=1CNCC1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 GBSOCQCTWPFEAX-UHFFFAOYSA-N 0.000 description 1
- MEPDXCIDJCRUHB-UHFFFAOYSA-N 5-[[(2,5-dimethylpyrazol-3-yl)methylamino]methyl]-1-ethyl-6-methyl-n-(oxan-4-yl)pyrazolo[3,4-b]pyridin-4-amine Chemical compound C=1C(C)=NN(C)C=1CNCC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 MEPDXCIDJCRUHB-UHFFFAOYSA-N 0.000 description 1
- KQXVZSJILWCLTC-UHFFFAOYSA-N 5-[[4-(benzenesulfonyl)piperazin-1-yl]methyl]-1-ethyl-6-methyl-n-(oxan-4-yl)pyrazolo[3,4-b]pyridin-4-amine Chemical compound C1CN(S(=O)(=O)C=2C=CC=CC=2)CCN1CC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 KQXVZSJILWCLTC-UHFFFAOYSA-N 0.000 description 1
- FBVCQEOPUHHLSJ-UHFFFAOYSA-N 5-[[4-(benzenesulfonyl)piperazin-1-yl]methyl]-1-ethyl-n-(oxan-4-yl)pyrazolo[3,4-b]pyridin-4-amine Chemical compound C1CN(S(=O)(=O)C=2C=CC=CC=2)CCN1CC1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 FBVCQEOPUHHLSJ-UHFFFAOYSA-N 0.000 description 1
- OFLQHUJQGHYUOQ-UHFFFAOYSA-N 5-[[[4-(dimethylamino)phenyl]methylamino]methyl]-1,6-diethyl-n-(oxan-4-yl)pyrazolo[3,4-b]pyridin-4-amine Chemical compound C=1C=C(N(C)C)C=CC=1CNCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 OFLQHUJQGHYUOQ-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- NVOYVOBDTVTBDX-AGUVMIOSSA-N 8g15t83e6i Chemical class C1([C@@H](CO)C(=O)OC2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CC)=CC=CC=C1 NVOYVOBDTVTBDX-AGUVMIOSSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
- 229940123025 Beta2 integrin antagonist Drugs 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102000017927 CHRM1 Human genes 0.000 description 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
- 101100296719 Caenorhabditis elegans pde-4 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 101150073075 Chrm1 gene Proteins 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Substances CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 229940122858 Elastase inhibitor Drugs 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- IYXGSMUGOJNHAZ-UHFFFAOYSA-N Ethyl malonate Chemical compound CCOC(=O)CC(=O)OCC IYXGSMUGOJNHAZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 101100296723 Homo sapiens PDE5A gene Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 101000988412 Homo sapiens cGMP-specific 3',5'-cyclic phosphodiesterase Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000003810 Jones reagent Substances 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241001071861 Lethrinus genivittatus Species 0.000 description 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229940126560 MAPK inhibitor Drugs 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- BXDZOYLPNAIDOC-UHFFFAOYSA-N N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]-1-[2-[2-[2-[2-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethoxy]ethoxy]ethoxy]ethylamino]-2-oxoethyl]piperidine-4-carboxamide Chemical compound CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCN(CC(=O)NCCOCCOCCOCCNc4cccc5C(=O)N(C6CCC(=O)NC6=O)C(=O)c45)CC3)s2)o1 BXDZOYLPNAIDOC-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 1
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- ZRZNJUXESFHSIO-UHFFFAOYSA-N Pleuromutilin Natural products CC1C(O)C(C)(C=C)CC(OC(=O)CO)C2(C)C(C)CCC31C2C(=O)CC3 ZRZNJUXESFHSIO-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 206010039094 Rhinitis perennial Diseases 0.000 description 1
- 208000036284 Rhinitis seasonal Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 229910006124 SOCl2 Inorganic materials 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- VPMWDFRZSIMDKW-YJYMSZOUSA-N Salmefamol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 VPMWDFRZSIMDKW-YJYMSZOUSA-N 0.000 description 1
- SZKKRCSOSQAJDE-UHFFFAOYSA-N Schradan Chemical group CN(C)P(=O)(N(C)C)OP(=O)(N(C)C)N(C)C SZKKRCSOSQAJDE-UHFFFAOYSA-N 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 241000269319 Squalius cephalus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- 241000656145 Thyrsites atun Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229940122598 Tryptase inhibitor Drugs 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- MVLPTSHEKQVKAL-UHFFFAOYSA-N [1-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]piperidin-4-yl]-phenylmethanone Chemical compound C1CC(C(=O)C=2C=CC=CC=2)CCN1CC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 MVLPTSHEKQVKAL-UHFFFAOYSA-N 0.000 description 1
- PIMCKEBFDVBTNK-UHFFFAOYSA-N [1-[[1-ethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]piperidin-4-yl]-phenylmethanone Chemical compound C1CC(C(=O)C=2C=CC=CC=2)CCN1CC1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 PIMCKEBFDVBTNK-UHFFFAOYSA-N 0.000 description 1
- NNCYCSNJPCKPDG-UHFFFAOYSA-N [4-[[1-ethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]piperazin-1-yl]-(furan-2-yl)methanone Chemical compound C1CN(C(=O)C=2OC=CC=2)CCN1CC1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 NNCYCSNJPCKPDG-UHFFFAOYSA-N 0.000 description 1
- JYKVAJHQGUFWRN-UHFFFAOYSA-N [4-[[1-ethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]piperazin-1-yl]-pyridin-2-ylmethanone Chemical compound C1CN(C(=O)C=2N=CC=CC=2)CCN1CC1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 JYKVAJHQGUFWRN-UHFFFAOYSA-N 0.000 description 1
- OIRDTQYFTABQOQ-KWTFZUJISA-N [C@@H]1([C@H](O)[C@H](O)[C@@H](C(O)[3H])O1)N1C(=NC=2C(N)=NC=NC12)[3H] Chemical compound [C@@H]1([C@H](O)[C@H](O)[C@@H](C(O)[3H])O1)N1C(=NC=2C(N)=NC=NC12)[3H] OIRDTQYFTABQOQ-KWTFZUJISA-N 0.000 description 1
- YFCGDEUVHLPRCZ-UHFFFAOYSA-N [dimethyl(trimethylsilyloxy)silyl]oxy-dimethyl-trimethylsilyloxysilane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C YFCGDEUVHLPRCZ-UHFFFAOYSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000004931 azocinyl group Chemical group N1=C(C=CC=CC=C1)* 0.000 description 1
- 229940028420 bactroban Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229950000210 beclometasone dipropionate Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- WGNZRLMOMHJUSP-UHFFFAOYSA-N benzotriazol-1-yloxy(tripyrrolidin-1-yl)phosphanium Chemical compound C1CCCN1[P+](N1CCCC1)(N1CCCC1)ON1C2=CC=CC=C2N=N1 WGNZRLMOMHJUSP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- OKTJSMMVPCPJKN-YPZZEJLDSA-N carbon-10 atom Chemical compound [10C] OKTJSMMVPCPJKN-YPZZEJLDSA-N 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- KSPYMJJKQMWWNB-UHFFFAOYSA-N cipamfylline Chemical compound O=C1N(CC2CC2)C(=O)C=2NC(N)=NC=2N1CC1CC1 KSPYMJJKQMWWNB-UHFFFAOYSA-N 0.000 description 1
- 229950002405 cipamfylline Drugs 0.000 description 1
- 229940119122 clarinex Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000037410 cognitive enhancement Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000012611 container material Substances 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 125000006311 cyclobutyl amino group Chemical group [H]N(*)C1([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 description 1
- 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- DDJSWKLBKSLAAZ-UHFFFAOYSA-N cyclotetrasiloxane Chemical compound O1[SiH2]O[SiH2]O[SiH2]O[SiH2]1 DDJSWKLBKSLAAZ-UHFFFAOYSA-N 0.000 description 1
- 230000020176 deacylation Effects 0.000 description 1
- 238000005947 deacylation reaction Methods 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 229960001271 desloratadine Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- MQYQOVYIJOLTNX-UHFFFAOYSA-N dichloromethane;n,n-dimethylformamide Chemical compound ClCCl.CN(C)C=O MQYQOVYIJOLTNX-UHFFFAOYSA-N 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- LTMHNWPUDSTBKD-UHFFFAOYSA-N diethyl 2-(ethoxymethylidene)propanedioate Chemical compound CCOC=C(C(=O)OCC)C(=O)OCC LTMHNWPUDSTBKD-UHFFFAOYSA-N 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940031661 dimethicone 350 Drugs 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- ODCCJTMPMUFERV-UHFFFAOYSA-N ditert-butyl carbonate Chemical compound CC(C)(C)OC(=O)OC(C)(C)C ODCCJTMPMUFERV-UHFFFAOYSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000003602 elastase inhibitor Substances 0.000 description 1
- 229940020485 elidel Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000000095 emetic effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- ZCRZCMUDOWDGOB-UHFFFAOYSA-N ethanesulfonimidic acid Chemical compound CCS(N)(=O)=O ZCRZCMUDOWDGOB-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000004634 feeding behavior Effects 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229920002457 flexible plastic Polymers 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008246 gaseous mixture Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical class O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- 229960001361 ipratropium bromide Drugs 0.000 description 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229940078545 isocetyl stearate Drugs 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- 229940060384 isostearyl isostearate Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- YYVLRNYCYCIGBO-UHFFFAOYSA-N n,n-dimethoxybenzenesulfonamide Chemical compound CON(OC)S(=O)(=O)C1=CC=CC=C1 YYVLRNYCYCIGBO-UHFFFAOYSA-N 0.000 description 1
- DPHDSIQHVGSITN-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-2-[1-[(4-fluorophenyl)methyl]-5-hydroxyindol-3-yl]-2-oxoacetamide Chemical compound C1=C(C(=O)C(=O)NC=2C(=CN=CC=2Cl)Cl)C2=CC(O)=CC=C2N1CC1=CC=C(F)C=C1 DPHDSIQHVGSITN-UHFFFAOYSA-N 0.000 description 1
- ZBGWAJQUDSCDPB-UHFFFAOYSA-N n-(benzenesulfonyl)benzamide Chemical compound C=1C=CC=CC=1C(=O)NS(=O)(=O)C1=CC=CC=C1 ZBGWAJQUDSCDPB-UHFFFAOYSA-N 0.000 description 1
- SBOZQGQOIFJITD-UHFFFAOYSA-N n-[3-[[[1-ethyl-6-methyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methylamino]methyl]phenyl]acetamide Chemical compound C=1C=CC(NC(C)=O)=CC=1CNCC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 SBOZQGQOIFJITD-UHFFFAOYSA-N 0.000 description 1
- SILOMELKUDKFDZ-UHFFFAOYSA-N n-[4-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methylsulfamoyl]phenyl]acetamide Chemical compound C=1C=C(NC(C)=O)C=CC=1S(=O)(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 SILOMELKUDKFDZ-UHFFFAOYSA-N 0.000 description 1
- VSRHWRLZAXUKDG-UHFFFAOYSA-N n-[4-[[1-ethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methylsulfamoyl]phenyl]acetamide Chemical compound C=1C=C(NC(C)=O)C=CC=1S(=O)(=O)NCC1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 VSRHWRLZAXUKDG-UHFFFAOYSA-N 0.000 description 1
- GAFPOIZXXIFFSC-UHFFFAOYSA-N n-[4-[[[1-ethyl-6-methyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methylamino]methyl]phenyl]acetamide Chemical compound C=1C=C(NC(C)=O)C=CC=1CNCC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 GAFPOIZXXIFFSC-UHFFFAOYSA-N 0.000 description 1
- STUOPWWJRREWSG-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-1,3-oxazole-5-carboxamide Chemical compound C=1N=COC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 STUOPWWJRREWSG-UHFFFAOYSA-N 0.000 description 1
- WUCVWNBIMTYZJQ-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-1,3-thiazole-5-carboxamide Chemical compound C=1N=CSC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 WUCVWNBIMTYZJQ-UHFFFAOYSA-N 0.000 description 1
- JRAVCWIXHRRTTP-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-1-phenylmethanesulfonamide Chemical compound C=1C=CC=CC=1CS(=O)(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 JRAVCWIXHRRTTP-UHFFFAOYSA-N 0.000 description 1
- KHBKHRLDDJRLNR-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCCC2=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 KHBKHRLDDJRLNR-UHFFFAOYSA-N 0.000 description 1
- WWNGVUNMWSQADU-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-2,4-difluorobenzamide Chemical compound C=1C=C(F)C=C(F)C=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 WWNGVUNMWSQADU-UHFFFAOYSA-N 0.000 description 1
- QWMXXYCSPBFUJB-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-2-ethoxypyridine-3-carboxamide Chemical compound CCOC1=NC=CC=C1C(=O)NCC1=C(CC)N=C(N(CC)N=C2)C2=C1NC1CCOCC1 QWMXXYCSPBFUJB-UHFFFAOYSA-N 0.000 description 1
- ZZTKVZFPRXIPDW-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-2-fluorobenzamide Chemical compound C=1C=CC=C(F)C=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 ZZTKVZFPRXIPDW-UHFFFAOYSA-N 0.000 description 1
- SUHPOELEVRCNGK-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-2-hydroxy-4-methylbenzamide Chemical compound C=1C=C(C)C=C(O)C=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 SUHPOELEVRCNGK-UHFFFAOYSA-N 0.000 description 1
- CCRZEGNIQUNNKW-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-2-methyl-1,3-oxazole-4-carboxamide Chemical compound C=1OC(C)=NC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 CCRZEGNIQUNNKW-UHFFFAOYSA-N 0.000 description 1
- IDSSENNNXSPYFN-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-2-methyl-1,3-thiazole-4-carboxamide Chemical compound C=1SC(C)=NC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 IDSSENNNXSPYFN-UHFFFAOYSA-N 0.000 description 1
- VZRRLXKGYQSBFP-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-2-methylpyrazole-3-carboxamide Chemical compound C=1C=NN(C)C=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 VZRRLXKGYQSBFP-UHFFFAOYSA-N 0.000 description 1
- NHVLGSVINBLVON-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-2-propan-2-ylpyrimidine-5-carboxamide Chemical compound C=1N=C(C(C)C)N=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 NHVLGSVINBLVON-UHFFFAOYSA-N 0.000 description 1
- CQNHTLKXAUBDGW-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-3-fluoropyridine-4-carboxamide Chemical compound C=1C=NC=C(F)C=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 CQNHTLKXAUBDGW-UHFFFAOYSA-N 0.000 description 1
- NWKLSHNGBDDACQ-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-3-oxo-1,2-dihydroindazole-6-carboxamide Chemical compound C=1C=C(C(NN2)=O)C2=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 NWKLSHNGBDDACQ-UHFFFAOYSA-N 0.000 description 1
- WPAKZSGAQCJSOX-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-fluorobenzamide Chemical compound C=1C=C(F)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 WPAKZSGAQCJSOX-UHFFFAOYSA-N 0.000 description 1
- URKHLSDPQAIEEG-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-5,6,7,8-tetrahydronaphthalene-2-carboxamide Chemical compound C=1C=C2CCCCC2=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 URKHLSDPQAIEEG-UHFFFAOYSA-N 0.000 description 1
- XSHNYAUIBLBZTN-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-5-methyl-1,2-oxazole-3-carboxamide Chemical compound C1=C(C)ON=C1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 XSHNYAUIBLBZTN-UHFFFAOYSA-N 0.000 description 1
- VOMDDJHEZXVUBQ-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-5-pyridin-2-ylthiophene-2-sulfonamide Chemical compound C=1C=C(C=2N=CC=CC=2)SC=1S(=O)(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 VOMDDJHEZXVUBQ-UHFFFAOYSA-N 0.000 description 1
- WRCRUXMTTCVPDT-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]butane-1-sulfonamide Chemical compound CCCCS(=O)(=O)NCC1=C(CC)N=C2N(CC)N=CC2=C1NC1CCOCC1 WRCRUXMTTCVPDT-UHFFFAOYSA-N 0.000 description 1
- DWQMGDOVPZGJBV-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]furan-2-carboxamide Chemical compound C=1C=COC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 DWQMGDOVPZGJBV-UHFFFAOYSA-N 0.000 description 1
- XRWFAWGHUFVJJR-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]furan-3-carboxamide Chemical compound C1=COC=C1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 XRWFAWGHUFVJJR-UHFFFAOYSA-N 0.000 description 1
- XZFLVEZUUMKGJB-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]morpholine-4-carboxamide Chemical compound C1COCCN1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 XZFLVEZUUMKGJB-UHFFFAOYSA-N 0.000 description 1
- OJOVETQVLIPWMP-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]naphthalene-1-carboxamide Chemical compound C=1C=CC2=CC=CC=C2C=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 OJOVETQVLIPWMP-UHFFFAOYSA-N 0.000 description 1
- XXHGHXRPKRZMCY-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]naphthalene-2-carboxamide Chemical compound C=1C=C2C=CC=CC2=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 XXHGHXRPKRZMCY-UHFFFAOYSA-N 0.000 description 1
- JALUYJBQHCIQNA-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]piperidine-1-carboxamide Chemical compound C1CCCCN1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 JALUYJBQHCIQNA-UHFFFAOYSA-N 0.000 description 1
- FLZMNWJMEVSKNF-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]propanamide Chemical compound CCC(=O)NCC1=C(CC)N=C2N(CC)N=CC2=C1NC1CCOCC1 FLZMNWJMEVSKNF-UHFFFAOYSA-N 0.000 description 1
- KZYSLRQLOCQDIQ-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]propane-2-sulfonamide Chemical compound CC(C)S(=O)(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 KZYSLRQLOCQDIQ-UHFFFAOYSA-N 0.000 description 1
- VUAQHBDTBXEHIE-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]pyrazine-2-carboxamide Chemical compound C=1N=CC=NC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 VUAQHBDTBXEHIE-UHFFFAOYSA-N 0.000 description 1
- GZAUOURTYDYGFK-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]pyrimidine-5-carboxamide Chemical compound C=1N=CN=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 GZAUOURTYDYGFK-UHFFFAOYSA-N 0.000 description 1
- OLEOJAXHKHMQGU-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]pyrrolidine-1-carboxamide Chemical compound C1CCCN1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 OLEOJAXHKHMQGU-UHFFFAOYSA-N 0.000 description 1
- DANNIOHDAYMXGC-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]thiophene-3-carboxamide Chemical compound C1=CSC=C1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 DANNIOHDAYMXGC-UHFFFAOYSA-N 0.000 description 1
- QNUIFPKBFRLZKA-UHFFFAOYSA-N n-[[1-ethyl-4-(oxan-4-ylamino)-6-(trifluoromethyl)pyrazolo[3,4-b]pyridin-5-yl]methyl]-2-methyl-1,3-thiazole-5-carboxamide Chemical compound C=1N=C(C)SC=1C(=O)NCC1=C(C(F)(F)F)N=C2N(CC)N=CC2=C1NC1CCOCC1 QNUIFPKBFRLZKA-UHFFFAOYSA-N 0.000 description 1
- WPTXWNACIMHWEJ-UHFFFAOYSA-N n-[[1-ethyl-4-(oxan-4-ylamino)-6-(trifluoromethyl)pyrazolo[3,4-b]pyridin-5-yl]methyl]-5-methylpyrazine-2-carboxamide Chemical compound C=1N=C(C)C=NC=1C(=O)NCC1=C(C(F)(F)F)N=C2N(CC)N=CC2=C1NC1CCOCC1 WPTXWNACIMHWEJ-UHFFFAOYSA-N 0.000 description 1
- LFTMWPICCDJXNM-UHFFFAOYSA-N n-[[1-ethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-1,2-oxazole-5-carboxamide Chemical compound C=1C=NOC=1C(=O)NCC1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 LFTMWPICCDJXNM-UHFFFAOYSA-N 0.000 description 1
- YINGUTXQYBXTBV-UHFFFAOYSA-N n-[[1-ethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-1-phenylmethanesulfonamide Chemical compound C=1C=CC=CC=1CS(=O)(=O)NCC1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 YINGUTXQYBXTBV-UHFFFAOYSA-N 0.000 description 1
- BWLTWJWKNMGRKD-UHFFFAOYSA-N n-[[1-ethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-2,2,2-trifluoroacetamide Chemical compound FC(F)(F)C(=O)NCC1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 BWLTWJWKNMGRKD-UHFFFAOYSA-N 0.000 description 1
- MOSMVGAINJSPIP-UHFFFAOYSA-N n-[[1-ethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-2-phenylacetamide Chemical compound C=1C=CC=CC=1CC(=O)NCC1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 MOSMVGAINJSPIP-UHFFFAOYSA-N 0.000 description 1
- QPBRFGATPZDOML-UHFFFAOYSA-N n-[[1-ethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-3,3-dimethylbutanamide Chemical compound CC(C)(C)CC(=O)NCC1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 QPBRFGATPZDOML-UHFFFAOYSA-N 0.000 description 1
- OGQODXQRPLHLMZ-UHFFFAOYSA-N n-[[1-ethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-5-pyridin-2-ylthiophene-2-sulfonamide Chemical compound C=1C=C(C=2N=CC=CC=2)SC=1S(=O)(=O)NCC1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 OGQODXQRPLHLMZ-UHFFFAOYSA-N 0.000 description 1
- RPNMRBILTXMKCJ-UHFFFAOYSA-N n-[[1-ethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-n',n'-dimethylbutanediamide Chemical compound CN(C)C(=O)CCC(=O)NCC1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 RPNMRBILTXMKCJ-UHFFFAOYSA-N 0.000 description 1
- RWKRBSJLJWOMIB-UHFFFAOYSA-N n-[[1-ethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-n-methyl-1,2-oxazole-5-carboxamide Chemical compound C=1C=NOC=1C(=O)N(C)CC1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 RWKRBSJLJWOMIB-UHFFFAOYSA-N 0.000 description 1
- PWTXNYDXANKKLR-UHFFFAOYSA-N n-[[1-ethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]benzamide Chemical compound C=1C=CC=CC=1C(=O)NCC1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 PWTXNYDXANKKLR-UHFFFAOYSA-N 0.000 description 1
- QTTSNMSNRQQEAT-UHFFFAOYSA-N n-[[1-ethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]benzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)NCC1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 QTTSNMSNRQQEAT-UHFFFAOYSA-N 0.000 description 1
- FZRBEDPUVGIPPZ-UHFFFAOYSA-N n-[[1-ethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]propanamide Chemical compound CCC(=O)NCC1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 FZRBEDPUVGIPPZ-UHFFFAOYSA-N 0.000 description 1
- YDVDLRYLSWWWAJ-UHFFFAOYSA-N n-[[1-ethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NCC1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 YDVDLRYLSWWWAJ-UHFFFAOYSA-N 0.000 description 1
- QYGRGYIUBQFEGL-UHFFFAOYSA-N n-[[1-ethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]pyridine-4-carboxamide Chemical compound C=1C=NC=CC=1C(=O)NCC1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 QYGRGYIUBQFEGL-UHFFFAOYSA-N 0.000 description 1
- GDZGAVRPANGZFU-UHFFFAOYSA-N n-[[1-ethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]thiophene-2-sulfonamide Chemical compound C=1C=CSC=1S(=O)(=O)NCC1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 GDZGAVRPANGZFU-UHFFFAOYSA-N 0.000 description 1
- FECIEKMYNKIPOL-UHFFFAOYSA-N n-[[1-ethyl-6-methyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-1,3-oxazole-5-carboxamide Chemical compound C=1N=COC=1C(=O)NCC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 FECIEKMYNKIPOL-UHFFFAOYSA-N 0.000 description 1
- YNLQUJHVUQDXKX-UHFFFAOYSA-N n-[[1-ethyl-6-methyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-1-phenylmethanesulfonamide Chemical compound C=1C=CC=CC=1CS(=O)(=O)NCC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 YNLQUJHVUQDXKX-UHFFFAOYSA-N 0.000 description 1
- BJNHPFCGRISXDV-UHFFFAOYSA-N n-[[1-ethyl-6-methyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCCC2=CC=1C(=O)NCC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 BJNHPFCGRISXDV-UHFFFAOYSA-N 0.000 description 1
- KVMGYFHAQRYXMJ-UHFFFAOYSA-N n-[[1-ethyl-6-methyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-2-fluorobenzamide Chemical compound C=1C=CC=C(F)C=1C(=O)NCC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 KVMGYFHAQRYXMJ-UHFFFAOYSA-N 0.000 description 1
- CCDBVPNPQAQUDQ-UHFFFAOYSA-N n-[[1-ethyl-6-methyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-2-hydroxy-4-methylbenzamide Chemical compound C=1C=C(C)C=C(O)C=1C(=O)NCC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 CCDBVPNPQAQUDQ-UHFFFAOYSA-N 0.000 description 1
- TZCJKIWLOBEZMH-UHFFFAOYSA-N n-[[1-ethyl-6-methyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-2-hydroxybenzamide Chemical compound C=1C=CC=C(O)C=1C(=O)NCC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 TZCJKIWLOBEZMH-UHFFFAOYSA-N 0.000 description 1
- DYILOTDOUNPZLO-UHFFFAOYSA-N n-[[1-ethyl-6-methyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-2-propan-2-ylpyrimidine-5-carboxamide Chemical compound C=1N=C(C(C)C)N=CC=1C(=O)NCC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 DYILOTDOUNPZLO-UHFFFAOYSA-N 0.000 description 1
- RLGONFCTFRKKCW-UHFFFAOYSA-N n-[[1-ethyl-6-methyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-3,3-dimethylbutanamide Chemical compound CC(C)(C)CC(=O)NCC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 RLGONFCTFRKKCW-UHFFFAOYSA-N 0.000 description 1
- HLDDWAGCJNTMCW-UHFFFAOYSA-N n-[[1-ethyl-6-methyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-3-oxo-1,2-dihydroindazole-6-carboxamide Chemical compound C=1C=C(C(NN2)=O)C2=CC=1C(=O)NCC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 HLDDWAGCJNTMCW-UHFFFAOYSA-N 0.000 description 1
- RLCONLFWEQSPQJ-UHFFFAOYSA-N n-[[1-ethyl-6-methyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-6-pyrrol-1-ylpyridine-3-carboxamide Chemical compound C=1C=C(N2C=CC=C2)N=CC=1C(=O)NCC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 RLCONLFWEQSPQJ-UHFFFAOYSA-N 0.000 description 1
- FHTRFUPBBMAUBQ-UHFFFAOYSA-N n-[[1-ethyl-6-methyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-n',n'-dimethylbutanediamide Chemical compound CN(C)C(=O)CCC(=O)NCC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 FHTRFUPBBMAUBQ-UHFFFAOYSA-N 0.000 description 1
- ZBGNVNJHKPRYOU-UHFFFAOYSA-N n-[[1-ethyl-6-methyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]butane-1-sulfonamide Chemical compound CCCCS(=O)(=O)NCC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 ZBGNVNJHKPRYOU-UHFFFAOYSA-N 0.000 description 1
- AFWJJQJBNQQWJN-UHFFFAOYSA-N n-[[1-ethyl-6-methyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]ethanesulfonamide Chemical compound CCS(=O)(=O)NCC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 AFWJJQJBNQQWJN-UHFFFAOYSA-N 0.000 description 1
- RTIQQPXZEOCJOZ-UHFFFAOYSA-N n-[[1-ethyl-6-methyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]furan-2-carboxamide Chemical compound C=1C=COC=1C(=O)NCC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 RTIQQPXZEOCJOZ-UHFFFAOYSA-N 0.000 description 1
- RUWDDTNAPFYSFP-UHFFFAOYSA-N n-[[1-ethyl-6-methyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]furan-3-carboxamide Chemical compound C1=COC=C1C(=O)NCC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 RUWDDTNAPFYSFP-UHFFFAOYSA-N 0.000 description 1
- PMAWXRLXMXNVDU-UHFFFAOYSA-N n-[[1-ethyl-6-methyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]morpholine-4-carboxamide Chemical compound C1COCCN1C(=O)NCC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 PMAWXRLXMXNVDU-UHFFFAOYSA-N 0.000 description 1
- NJAZPNUOPNGJAH-UHFFFAOYSA-N n-[[1-ethyl-6-methyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]propane-2-sulfonamide Chemical compound CC(C)S(=O)(=O)NCC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 NJAZPNUOPNGJAH-UHFFFAOYSA-N 0.000 description 1
- YVETVGBGVCJHSB-UHFFFAOYSA-N n-[[1-ethyl-6-methyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]pyrazine-2-carboxamide Chemical compound C=1N=CC=NC=1C(=O)NCC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 YVETVGBGVCJHSB-UHFFFAOYSA-N 0.000 description 1
- HTJXNZAUEPIBOY-UHFFFAOYSA-N n-[[1-ethyl-6-methyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]pyrrolidine-1-carboxamide Chemical compound C1CCCN1C(=O)NCC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 HTJXNZAUEPIBOY-UHFFFAOYSA-N 0.000 description 1
- KKKVOIIIFDVTFT-UHFFFAOYSA-N n-[[1-ethyl-6-methyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]thiophene-2-sulfonamide Chemical compound C=1C=CSC=1S(=O)(=O)NCC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 KKKVOIIIFDVTFT-UHFFFAOYSA-N 0.000 description 1
- WZLAQHNTZOPCAW-UHFFFAOYSA-N n-ethyl-n-[[1-ethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-1,2-oxazole-5-carboxamide Chemical compound C=1C=NOC=1C(=O)N(CC)CC1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 WZLAQHNTZOPCAW-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000000236 nitric oxide synthase inhibitor Substances 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 208000037916 non-allergic rhinitis Diseases 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 description 1
- 229960000797 oxitropium Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000011049 pearl Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 208000022719 perennial allergic rhinitis Diseases 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- NAYYNDKKHOIIOD-UHFFFAOYSA-N phthalamide Chemical compound NC(=O)C1=CC=CC=C1C(N)=O NAYYNDKKHOIIOD-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- ZRZNJUXESFHSIO-VYTKZBNOSA-N pleuromutilin Chemical compound C([C@H]([C@]1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]2C)OC(=O)CO)C)C[C@]32[C@H]1C(=O)CC3 ZRZNJUXESFHSIO-VYTKZBNOSA-N 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229940112971 protopic Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000004941 pyridazin-5-yl group Chemical group N1=NC=CC(=C1)* 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 238000003044 randomized block design Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- STZYTFJPGGDRJD-NHUWBDDWSA-N retapamulin Chemical compound C([C@H]([C@@]1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]2C)OC(=O)CS[C@@H]3C[C@H]4CC[C@H](N4C)C3)C)C[C@]32[C@H]1C(=O)CC3 STZYTFJPGGDRJD-NHUWBDDWSA-N 0.000 description 1
- 229960002771 retapamulin Drugs 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- CSYSULGPHGCBQD-UHFFFAOYSA-N s-ethylisothiouronium diethylphosphate Chemical compound CCSC(N)=N.CCOP(O)(=O)OCC CSYSULGPHGCBQD-UHFFFAOYSA-N 0.000 description 1
- 229960000581 salicylamide Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229950001879 salmefamol Drugs 0.000 description 1
- 229960005018 salmeterol xinafoate Drugs 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 208000017022 seasonal allergic rhinitis Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000010956 selective crystallization Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000003579 shift reagent Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940098760 steareth-2 Drugs 0.000 description 1
- 229940100458 steareth-21 Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 150000003461 sulfonyl halides Chemical class 0.000 description 1
- 230000006103 sulfonylation Effects 0.000 description 1
- 238000005694 sulfonylation reaction Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229940110309 tiotropium Drugs 0.000 description 1
- 229960000257 tiotropium bromide Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- 239000002750 tryptase inhibitor Substances 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 208000001319 vasomotor rhinitis Diseases 0.000 description 1
- DAFYYTQWSAWIGS-DEOSSOPVSA-N vilanterol Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCCCCCOCCOCC=2C(=CC=CC=2Cl)Cl)=C1 DAFYYTQWSAWIGS-DEOSSOPVSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72159705P | 2005-09-29 | 2005-09-29 | |
| US721597P | 2005-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2363795T3 true ES2363795T3 (es) | 2011-08-16 |
Family
ID=37685723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES06779578T Active ES2363795T3 (es) | 2005-09-29 | 2006-09-29 | Compuestos de pirazolo[3,4-b]piridina, y su uso como inhibidores de pde4. |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20090131431A1 (enExample) |
| EP (2) | EP1940835B1 (enExample) |
| JP (2) | JP2009510044A (enExample) |
| AT (1) | ATE503756T1 (enExample) |
| DE (1) | DE602006021044D1 (enExample) |
| ES (1) | ES2363795T3 (enExample) |
| WO (2) | WO2007036734A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090131431A1 (en) * | 2005-09-29 | 2009-05-21 | Christopher David Edlin | Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors |
| GB0614570D0 (en) * | 2006-07-21 | 2006-08-30 | Glaxo Group Ltd | Compounds |
| NZ574533A (en) | 2006-08-01 | 2011-05-27 | Glaxo Group Ltd | Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors |
| SI2124944T1 (sl) | 2007-03-14 | 2012-05-31 | Ranbaxy Lab Ltd | Derivati pirazolo b piridina kot inhibitorji fosfodiesteraze |
| WO2008136382A1 (ja) | 2007-04-26 | 2008-11-13 | Takeda Pharmaceutical Company Limited | 二環性化合物およびその医薬用途 |
| EP2249646A4 (en) * | 2008-02-06 | 2013-09-25 | Glaxo Group Ltd | PDE4 muscarinic Antagonist-DOPPELPHARMACOPHOREN |
| WO2009100170A1 (en) * | 2008-02-06 | 2009-08-13 | Glaxo Group Limited | Dual pharmacophores - pde4-muscarinic antagonistics |
| EP2346867A1 (en) * | 2008-09-19 | 2011-07-27 | Ranbaxy Laboratories Limited | Phosphodiestarase inhibitors |
| CA2749403A1 (en) | 2009-01-13 | 2010-09-02 | Glaxo Group Limited | Pyrimidinecarboxamide derivatives as inhibitors of syk kinase |
| EP2547664B1 (de) * | 2010-03-16 | 2016-05-04 | Merck Patent GmbH | Morpholinylchinazoline |
| US8487102B2 (en) * | 2010-04-20 | 2013-07-16 | Hoffmann-La Roche Inc. | Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists |
| WO2012061926A1 (en) * | 2010-11-08 | 2012-05-18 | Zalicus Pharmaceuticals Ltd. | Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers |
| EP2574607A1 (en) * | 2011-09-06 | 2013-04-03 | F. Hoffmann-La Roche AG | PDE10 modulators |
| US9243001B2 (en) | 2013-03-15 | 2016-01-26 | Epizyme, Inc. | Substituted benzene compounds |
| US20160031907A1 (en) * | 2013-03-15 | 2016-02-04 | Epizyme, Inc. | Substituted Benzene Compounds |
| US9011934B2 (en) | 2013-06-14 | 2015-04-21 | SatisPharma, LLC | Multi-purpose anti-itch treatment |
| DK3102576T3 (da) | 2014-02-03 | 2019-07-22 | Vitae Pharmaceuticals Llc | Dihydropyrrolopyridininhibitorer af ror-gamma |
| DE102014009164A1 (de) * | 2014-06-03 | 2015-12-03 | Herbalist & Doc Gesundheitsgesellschaft Mbh | Silikonölhaltige nasal anzuwendende Formulierungen |
| SI3207043T1 (sl) | 2014-10-14 | 2019-04-30 | Vitae Pharmaceuticals, Inc. | Dihidropirolopiridinovi inhibitorji za ROR-gama |
| US9452178B1 (en) | 2014-10-22 | 2016-09-27 | SatisPharma, LLC | Acne formulations, treatments, and pressure sensitive patches for delivery of acne formulations |
| US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| EP3331876B1 (en) | 2015-08-05 | 2020-10-07 | Vitae Pharmaceuticals, LLC | Modulators of ror-gamma |
| EP3868750A1 (en) | 2015-11-20 | 2021-08-25 | Vitae Pharmaceuticals, LLC | Modulators of ror-gamma |
| TWI757266B (zh) | 2016-01-29 | 2022-03-11 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| US20200087271A1 (en) | 2016-12-20 | 2020-03-19 | Syngenta Participations Ag | N-cyclobutyl-thiazol-5-carboxamides with nematicidal activity |
| MA49014A (fr) * | 2017-03-21 | 2020-02-05 | Arbutus Biopharma Corp | Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| CN115716826A (zh) | 2017-07-24 | 2023-02-28 | 生命医药有限责任公司 | RORγ的抑制剂 |
| TW201920188A (zh) * | 2017-08-10 | 2019-06-01 | 美商美國禮來大藥廠 | [1,2,4]三唑衍生物 |
| WO2019147824A1 (en) | 2018-01-26 | 2019-08-01 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor |
| CN113348011B (zh) | 2018-11-19 | 2023-04-18 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| JP7677983B2 (ja) * | 2020-01-23 | 2025-05-15 | マイオフォルテ セラピューティクス，インク． | Ｐｇｄｈ阻害剤、およびその作製と使用の方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0314392A (pt) * | 2002-09-16 | 2005-07-12 | Glaxo Group Ltd | Composto ou um sal do mesmo, composição farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de uma doença inflamatória e/ou alérgica ou deficiência cognitiva em um mamìfero, e, combinação |
| GB0230045D0 (en) * | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
| US20090131431A1 (en) * | 2005-09-29 | 2009-05-21 | Christopher David Edlin | Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors |
-
2006
- 2006-09-29 US US12/067,990 patent/US20090131431A1/en not_active Abandoned
- 2006-09-29 WO PCT/GB2006/003627 patent/WO2007036734A1/en not_active Ceased
- 2006-09-29 JP JP2008532874A patent/JP2009510044A/ja active Pending
- 2006-09-29 DE DE602006021044T patent/DE602006021044D1/de active Active
- 2006-09-29 WO PCT/GB2006/003626 patent/WO2007036733A1/en not_active Ceased
- 2006-09-29 AT AT06779578T patent/ATE503756T1/de not_active IP Right Cessation
- 2006-09-29 EP EP06779578A patent/EP1940835B1/en active Active
- 2006-09-29 JP JP2008532873A patent/JP5323484B2/ja not_active Expired - Fee Related
- 2006-09-29 ES ES06779578T patent/ES2363795T3/es active Active
- 2006-09-29 EP EP06779579A patent/EP1940836A1/en not_active Withdrawn
- 2006-09-29 US US12/067,994 patent/US20080255186A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20090131431A1 (en) | 2009-05-21 |
| US20080255186A1 (en) | 2008-10-16 |
| EP1940835B1 (en) | 2011-03-30 |
| WO2007036733A1 (en) | 2007-04-05 |
| EP1940836A1 (en) | 2008-07-09 |
| JP2009510043A (ja) | 2009-03-12 |
| JP2009510044A (ja) | 2009-03-12 |
| DE602006021044D1 (de) | 2011-05-12 |
| JP5323484B2 (ja) | 2013-10-23 |
| WO2007036734A1 (en) | 2007-04-05 |
| ATE503756T1 (de) | 2011-04-15 |
| EP1940835A1 (en) | 2008-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1940835B1 (en) | Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors | |
| ES2331119T3 (es) | Compuestos de pirazolo(3,4-b)piridina, y su uso como inhibidores de fosfodiesterasa. | |
| US7709497B2 (en) | Pyrazolo[3,4-b]pyridine compound, and its use as a PDE4 inhibitor | |
| ES2345385T3 (es) | Compuestos de pirazolo(3,4-b)piridina, y su uso como inhibidores de fosfodiesterasa. | |
| US20080132536A1 (en) | Pyrazolo [3,4-b] pyridine compounds, and their use as pde4 inhibitors | |
| WO2005090348A1 (en) | Pyrazolo ’3,4-b! pyridine compounds, and their use as phosphodiesterase type 4 (pde4) inhibitors | |
| JP2007529484A (ja) | ピラゾロ［３，４−ｂ］ピリジン化合物、およびＰＤＥ４阻害剤としてのその使用 | |
| US20090318494A1 (en) | Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors | |
| US20090326003A1 (en) | Pyrazolo (3, 4-b) pyridine derivatives as pde4 inhibitors | |
| ES2362445T3 (es) | Compuestos de pirazolo[3,4-b]piridina y su uso como inhibidores de pde4. | |
| MXPA06010486A (en) | Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor | |
| HK1127603B (en) | Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors |